Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002521 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy and Bone Marrow and/or Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma
A Phase 2 study, sponsored by Temple University.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00002521 is a Phase 2 study that has completed, run by Temple University.
The verdict
NCT00002521, a Phase 2 study, has completed, sponsored by Temple University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Bone marrow and peripheral stem cell transplantation may allow doctors to give high doses of chemotherapy and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy with cyclophosphamide, etoposide and cisplatin followed by bone marrow and/or peripheral stem cell transplantation in patients with relapsed or refractory intermediate- or high-grade non-Hodgkin's lymphoma.
Interventions
- DRUG cisplatin
- DRUG cyclophosphamide
- DRUG etoposide
- PROCEDURE bone marrow ablation with stem cell support
- PROCEDURE autologous bone marrow transplantation
Trial Details
| Field | Value |
|---|---|
| Start Date | 1993-02 |
| Est. Completion | 2000-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002521
The ClinicalTrials.gov registry entry for NCT00002521 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Temple University, which has 163 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cisplatin is the first listed.
NCT00002521 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002521 about?
NCT00002521 is a clinical study titled "Combination Chemotherapy and Bone Marrow and/or Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Bone marrow and peripheral stem cell transplantation may allow doctors to give high doses of chemotherapy and kill more tumor cells. PURPOSE: Phase II trial to study the effective...
What is the current status of trial NCT00002521?
This trial is currently completed. It is a Phase 2 study. The study started on 1993-02. Estimated completion is 2000-02.
What interventions are being tested in trial NCT00002521?
The interventions under investigation include: cisplatin (DRUG), cyclophosphamide (DRUG), etoposide (DRUG), bone marrow ablation with stem cell support (PROCEDURE), autologous bone marrow transplantation (PROCEDURE).
Who is sponsoring clinical trial NCT00002521?
This trial is sponsored by Temple University, which has 163 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.